Five-Year-Old Dies After Taking Cough Syrup in Rajasthan; State Orders Urgent Probe

The child, identified as Nityansh Sharma, reportedly consumed the cough syrup obtained from a government Community Health Centre (CHC) in Sikar late Sunday night and was found dead the following morning.

Five-Year-Old Dies After Taking Cough Syrup in Rajasthan; State Orders Urgent Probe
News

The death of a five-year-old boy in Sikar district late Monday following administration of a dextromethorphan-based cough syrup has triggered alarm across health authorities, prompting an immediate investigation into the safety and distribution of the medicine.

The child, identified as Nityansh Sharma, reportedly consumed the cough syrup obtained from a government Community Health Centre (CHC) in Sikar late Sunday night and was found dead the following morning. While the boy’s family has accused the syrup of causing his demise, local health officials have so far declined to confirm a direct causal link.

Concerns escalated further after reports emerged that several children in Sikar and neighboring Bharatpur districts exhibited symptoms such as vomiting, drowsiness, dizziness, restlessness, anxiety, and even unconsciousness after taking the same medicine.

In response, Rajasthan’s Health Minister Gajendra Khimsar has ordered a full probe into the incident and called for swift remedial measures. The Rajasthan Medical Services Corporation Ltd (RMSCL) has already moved to ban distribution of the specific batch of cough syrup implicated in the case.

Dr. Ashok Maharia, Chief Medical Health Officer of Sikar, stated that the boy had reportedly been administered the medicine three days earlier at the CHC. However, by the time he was brought to SK Hospital on Monday, he was already deceased. Meanwhile, villagers allege negligence, saying the child took the syrup at night and was found dead the following morning.

As the case unfolds, authorities face mounting scrutiny over pharmaceutical safety protocols and accountability in rural health delivery systems. The probe’s findings could have far-reaching implications for regulation of pediatric medicines and drug distribution in public health facilities.